Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03610490 · ClinicalTrials.gov registry record · Phase 2
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT03610490: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT03610490 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03610490, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This phase II trial studies how well autologous tumor infiltrating lymphocytes MDA-TIL works in treating patients with ovarian cancer, colorectal cancer, or pancreatic ductal adenocarcinoma that has come back (recurrent) or does not respond to treatment (refractory). Autologous tumor infiltrating lymphocytes MDA-TIL, made by collecting and growing specialized white blood cells (called T-cells) from a patient's tumor, may help to stimulate the immune system in different ways to stop tumor cells from growing.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- OTHER Quality-of-Life Assessment
- BIOLOGICAL Interleukin-2
- BIOLOGICAL Autologous Tumor Infiltrating Lymphocytes MDA-TIL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-10-16 |
| Est. Completion | 2024-08-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03610490
The ClinicalTrials.gov registry entry for NCT03610490 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT03610490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03610490 about?
NCT03610490 is a clinical study titled "Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma". This phase II trial studies how well autologous tumor infiltrating lymphocytes MDA-TIL works in treating patients with ovarian cancer, colorectal cancer, or pancreatic ductal adenocarcinoma that has come back (recurrent) or does not respond to treatment (refractory). Autologous tumor infiltrating ly...
What is the current status of trial NCT03610490?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2018-10-16. Estimated completion is 2024-08-21.
What interventions are being tested in trial NCT03610490?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Quality-of-Life Assessment (OTHER), Interleukin-2 (BIOLOGICAL), Autologous Tumor Infiltrating Lymphocytes MDA-TIL (BIOLOGICAL).
Who is sponsoring clinical trial NCT03610490?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.